Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wolska-Kusnierz, B; Pastorczak, A; Fendler, W; Wakulinska, A; Dembowska-Baginska, B; Heropolitanska-Pliszka, E; Piątosa, B; Pietrucha, B; Kałwak, K; Ussowicz, M; Pieczonka, A; Drabko, K; Lejman, M; Koltan, S; Gozdzik, J; Styczynski, J; Fedorova, A; Miakova, N; Deripapa, E; Kostyuchenko, L; Krenova, Z; Hlavackova, E; Gennery, AR; Sykora, KW; Ghosh, S; Albert, MH; Balashov, D; Eapen, M; Svec, P; Seidel, MG; Kilic, SS; Tomaszewska, A; Wiesik-Szewczyk, E; Kreins, A; Greil, J; Buechner, J; Lund, B; Gregorek, H; Chrzanowska, K; Mlynarski, W.
Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome.
Clin Cancer Res. 2021; 27(2):575-584
Doi: 10.1158/1078-0432.CCR-20-2574
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Seidel Markus
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency. Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors n = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7-21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; P < 10-5). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; P = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138-0.162); P < 0.0001]. There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer. ©2020 American Association for Cancer Research.